T4071 |
Repotrectinib
|
1802220-02-5
|
99.86%
|
|
Repotrectinib (TPX-0005) is a potent ALK/ROS1/TRK inhibitor, with IC50 of 1.01 nM, 5.3 nM, 1.08 nM and 1.26 nM for WT ALK, SRC, ALK L1196M and ALK G1202R, respec...
|
T3935 |
1-Naphthyl PP1
|
221243-82-9
|
99.85%
|
|
1-Naphthyl PP1 (1-NA-PP 1) is a selective src inhibitor(v-Src and c-Fyn, c-Abl, CDK2 and CAMK II with IC50s of 1.0, 0.6, 0.6, 18 and 22 μM, respectively)
|
T1777 |
Nintedanib
|
656247-17-5
|
99.85%
|
|
Nintedanib (Intedanib) is a triple vascular kinase inhibitor that inhibits VEGFR1, VEGFR2, and VEGFR3 (IC50=34/13/13 nM), FGFR1, FGFR2, and FGFR3 (IC50=69/37/108...
|
T0152 |
Bosutinib
|
380843-75-4
|
99.84%
|
|
Bosutinib (SKI-606) is a synthetic quinolone derivative and dual kinase inhibitor that targets both Abl (IC50: 1 nM) and Src (IC50: 1.2 nM) kinases.
|
T2640 |
Rebastinib
|
1020172-07-9
|
99.84%
|
|
DCC-2036 (Rebastinib (DCC-2036)) is a conformational control Bcr-Abl inhibitor for Abl1(WT, IC50: 0.8 nM) and Abl1(T315I, IC50: 4 nM), also inhibits LYN, SRC, HC...
|
T6196 |
PP1
|
172889-26-8
|
99.82%
|
|
PP1 (AGL 1872), a specific and effective Src inhibitor, is with IC50 for Lck/Fyn is 5 nM/ 6 nM, respectively.
|
T6886 |
MCB-613
|
1162656-22-5
|
99.8%
|
|
MCB-613 is an effective steroid receptor coactivator (SRC) stimulator.
|
T1835 |
Ibrutinib
|
936563-96-1
|
99.79%
|
|
Ibrutinib (PCI-32765) is an irreversible inhibitor of BTK (IC50: 0.5 nM) that selectively blocks B cell activation.
|
TQ0169 |
Inulicin
|
33627-41-7
|
99.77%
|
|
Inulicin (1-O-Acetylbritannilactone), an active compound isolated from Inula Britannica L, inhibits VEGF-mediated activation of Src and FAK.
|
T77624 |
WAY-270250
|
852367-46-5
|
99.77%
|
|
WAY-270250 is an IGF-1R/SRC inhibitor.
|
T2624 |
OSI-930
|
728033-96-3
|
99.76%
|
|
OSI-930, an orally active inhibitor of c-Kit and the vascular endothelial growth factor receptor-2 (VEGFR-2), targets cancer cell proliferation and blood vessel ...
|
T32613 |
LCB 03-0110 dihydrochloride
|
1962928-28-4
|
99.76%
|
|
LCB 03-0110 Dihydrochloride is a potent inhibitor of the c-Src kinase (IC50 = 1.3 nM) and tyrosine kinases in the BTK and SYK family, as well as in the DDR2 fami...
|
T6321 |
Tofacitinib
|
477600-75-2
|
99.74%
|
|
Tofacitinib (Tasocitinib) is an oral, small molecule inhibitor of Janus kinases that is used to treat moderate-to-severe rheumatoid arthritis.
|
T1667 |
Tandutinib
|
387867-13-2
|
99.74%
|
|
Tandutinib (CT53518) (MLN518, CT53518), an effective FLT3 antagonist (IC50: 0.22 μM), can also inhibit c-Kit and PDGFR, 15-20 fold higher potency for FLT3 versus...
|
T2372 |
Ponatinib
|
943319-70-8
|
99.74%
|
|
Ponatinib (AP24534) is an orally available, multitargeted kinase inhibitor (IC50s: 0.37/1.1/1.5/2.2/5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively)...
|
T61360 |
ARN25068
|
2649882-80-2
|
99.71%
|
|
ARN25068 is a potent inhibitor of GSK-3β, FYN, and DYRK1A protein kinases, exerting its activity in the sub-micromolar range. This compound effectively addresses...
|
T13194 |
CSF1R-IN-2
|
2271119-26-5
|
99.71%
|
|
CSF1R-IN-2 is an oral-active SRC, MET and c-FMS inhibitor (IC50s: 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively).
|
T3319 |
Scutellarein
|
529-53-3
|
99.7%
|
|
Scutellarein (6-Hydroxyapigenin) reduces inflammatory responses by inhibiting Src kinase activity.
|
T6311 |
Bafetinib
|
859212-16-1
|
99.68%
|
|
Bafetinib (INNO-406) (INNO-406) is an effective and specific dual Bcr-Abl/Lyn inhibitor (IC50: 5.8/19 nM), and no inhibition of the phosphorylation of the T315I ...
|
T6345 |
Tirbanibulin
|
897016-82-9
|
99.67%
|
|
Tirbanibulin (KX2-391) is a highly selective Src kinase inhibitor that has demonstrated efficacy in pre-Clinicalal animal models of colon, pancreatic, prostate a...
|